ABCL635
- Indication
- Moderate-to-severe vasomotor symptoms (VMS) associated with menopause
- Stage
- phase1
- Event
- Topline Data
- Details
April 20, 2026: AbCellera (NASDAQ: ABCL) announced it will disclose interim results from the Phase 1 portion of its ABCL635 Phase 1/2 study during its Q1 2026 earnings call on May 11, 2026. The interim update is expected to include observed safety profile, pharmacokinetics, and pharmacodynamic target engagement data.
ABCL635 is a potential first-in-class antibody targeting the neurokinin 3 receptor (NK3R) for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. The program entered the clinic in July 2025.
Upcoming catalyst: Results from the ongoing multicenter, randomized, double-blind, placebo-controlled Phase 2 portion in postmenopausal women with moderate-to-severe vasomotor symptoms are anticipated in Q3 2026.
- Source
- View catalyst source ↗